Evidence map›Paper›PMID 33088975›Full record

ArticleHeliyon2020

Therapeutic effect of TRC105 and decitabine combination in AML xenografts.

June Baik, Martin Felices, Ashley Yingst, Charles P Theuer, Michael R Verneris, Jeffrey S Miller, Rita Perlingeiro

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

June BaikDept. of Medicine, University of Minnesota, Minneapolis, MN, USA.
Martin FelicesDept. of Medicine, University of Minnesota, Minneapolis, MN, USA.
Ashley YingstDept. of Pediatrics, University of Denver, Colorado, CO, USA.
Charles P TheuerTRACON Pharmaceuticals, Inc., San Diego, CA, USA.
Michael R VernerisDept. of Pediatrics, University of Denver, Colorado, CO, USA.
Jeffrey S MillerDept. of Medicine, University of Minnesota, Minneapolis, MN, USA.
Rita PerlingeiroDept. of Medicine, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USUniversity of Denver · USTracon Pharmaceuticals (United States) · US

Funding

TRAINING IN HEMOGLOBIN &CELL MEMBRANE RESEARCHT32HL007062 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller, Gregory M Vercellotti · 1985 to 2026
$10.3M
NHLBI NIH HHS T32 HL007062
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refractory AML patients, yet responses following DAC monotherapy are still modest. The transforming growth factor-β (TGF-β) receptor CD105 (endoglin) is expressed in various hematopoietic malignancies, and high CD105 expression correlates with poor prognosis in AML patients. Using a xenograft model, we have recently demonstrated that targeting CD105

Indexed as

AMLAntibodyCancer researchCell biologyChemotherapyDecitabineHematologyMolecular biologyTRC105Xenografts

Identifiers

PMID33088975
PMCPMC7566100
OpenAlexW3092812456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.